Pacran, the first product in the world to have demonstrated its effectiveness in fighting urinary tract infections from bacterial sources
Pacran® cranberry powder is unique and pushes industry standards for having clinically demonstrated (tests on humans) that it was effective:
- To help prevent (recurrent) urinary tract infections
- To help prevent recurrent urinary tract infections, in women
Made from whole cranberries (peel, pulp, seeds, juice) PACran powder® is standardized to proanthocyans
Made from whole American cranberry(vaccinium macrocarpon)with a defined proanthocyanidin concentration (PAC/P ro Anthocyanins Content), Pacran® powder contains the pulp, juice, seeds and peel of the fruits. Being whole, pacran powder® provides all the phenolic compounds, organic acids, fiber, proteins and finally the sugars of the American cranberry / macrocarpon.
Pacran® powder is standardized to always contain the same levels of active ingredients that have allowed the product to successfully pass clinical trials. To this end, Health Canada recognizes that 500 mg of Pacran powder® provides this efficacy, which is the amount found in each capsule of Phytonutrient Canada’s product, PC Pacran® + B Urinary Formula. Added to Pacran powder® a quantity of wild blueberry powder (+ B) just as whole as Pacran powder® which could serve as an adjuvent (material that added to a drug increases its effectiveness). However, this wild blueberry/PACran synergy effect has not been clinically demonstrated.
Cranberry powder Pacran® is 100% cranberry. No extraction solvents or flow agents are used. The product holds six U.S. and three international patents. Pacran®’s unparalleled level of justification has led Health Canada and also the Korean FDA to accept the powder as a medicinal ingredient.
The composition of Pacran® is as follows:
- PACs (HPLC) Larger than 1.5%
- PACs (Eur.Ph average value 7.2%
- PACs (BL DMAC) 0.4%
Whole cranberry matrices actually exceed PAC-rich fractions
While most of the latest generation cranberry products focus solely on the concentration of proanthocyanins/proanthocyanidins (PAC) type A, Naturex has used a different approach and conducted several clinical studies on Pacran® in order to obtain the evidence needed to obtain a PLA from Health Canada.
Clinical trials of Pacran® showed that with the intake of 500mg of Pacran®/ day, the group taking Pacran® experienced a 36% reduction in the presence of E. coli in urine compared to the group that took a placebo. These results show that a daily dose of Pacran® helps support a healthy urinary tract.
Another 180-day clinical trial was conducted on 176 women subject to ICU to assess Pacran®’s ability to reduce recurrent episodes. The results were that a daily dose of 500 mg of Pacran® reduced cystitis recurrences by 58% compared to placebo.
Evidence from research published in 2011 and 2012 suggests that whole cranberry matrices actually exceed PAC-rich fractions.
Nearly half of all women will experience a urinary tract infection in their lifetime, with some women being particularly susceptible to recurrent episodes. Cranberry consumption is traditionally associated with urinary tract
Pacran® is a studied and scientifically proven American cranberry product for urinary tract health.
Health Canada Product Monograph
SOURCE- HEALTH CANADA: Compendium of Medicinal Ingredients Nomenclature
Drugs and natural health products
Natural Product Number (NPN):
Recommended route of administration:
Recommended Uses or Purposes:
|List of medicinal ingredients:|
|Medicinal ingredients||Quantity (Qty)||Extract||Activity|
|Vaccinium macrocarpon||As authorized in the NHPD monograph(s) to which the applicant has attested|
List of non-medicinal ingredients:
Date of approval:
Date of licence amendment: